Physician profile
Stephen Kraus
NPI 1427035203
$1,050.24
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $938 · 2020: $113.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $210.56 | 2019 | |
| Allergan, INC. | $188.63 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $165.78 | 2019 | |
| Journey Medical Corporation | $145.51 | 2019 | |
| Janssen Biotech, INC. | $71.16 | 2019 | |
| Ucb, INC. | $62.38 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $61.61 | 2019 | |
| Sun Pharmaceutical Industries INC. | $58.78 | 2019 | |
| Galderma Laboratories, L.P. | $46.97 | 2019 | |
| Lilly USA, LLC | $38.86 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Kraus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.